Serina Therapeutics posted a net loss of USD 6.36 million in the quarter ended June 30, 2026, narrowing from USD 6.46 million.
Operating loss widened to USD 6.78 million as operating expenses climbed to USD 6.78 million from USD 5.7 million.
Research and development costs rose to USD 3.82 million from USD 3.15 million, driven by higher clinical activity and headcount.
General and administrative expense increased to USD 2.97 million from USD 2.54 million on higher legal spending tied to patent and financing.
Cash and cash equivalents totaled USD 23 million at June 30, 2026; management flagged substantial doubt about going concern without additional financing.
SERA•
